PureTech Health plc

PureTech Health plc a clinical stage biotherapeutics company engages in the discovery development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100 currently under Phase 3 stage to treat idiopathic pulmonary fibrosis (IPF); and LYT-200 a IgG4 monoclonal antibody currently under Phase 1/2 stage to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300 an oral allopregnanolone currently completed Phase 1 stage to treat depression anxiety and related indications; and LYT-310 an oral cannabidiol currently under preclinical stage to treat epilepsies and other neurological indications. In addition the company is developing LYT-503/IMB-150 a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis or bladder pain syndrome; and Glyph technology platform a lymphatic-targeting chemistry platform which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston Massachusetts.